OBJECTIVE: To evaluate joint tissue remodeling using the urinary collagen biomarkers urinary α-C-telopeptide of type I collagen (α-CTX) and urinary C-telopeptide of type II collagen (CTX-II) and to determine the association of these biomarkers with osteoarthritis (OA) severity, progression, and localized knee bone turnover. METHODS: Participants (n = 149) with symptomatic and radiographic knee OA underwent fixed-flexion knee radiography at baseline and 3 years, and late-phase bone scintigraphy of both knees at baseline, which were scored semiquantitatively for osteophyte and joint space narrowing (JSN) severity and uptake intensity, with scores summed across knees. Urinary concentrations of α-CTX and CTX-II were determined by enzyme-linked immunosorbent assay. Immunohistochemical analysis of human OA knees was performed to localize the joint tissue origin of the biomarker epitopes. RESULTS: Urinary α-CTX concentrations correlated strongly with the intensity of bone scintigraphic uptake and with JSN progression (risk ratio 13.2) and osteophyte progression (risk ratio 3). Urinary CTX-II concentrations were strongly associated with intensity of bone scintigraphic uptake, with JSN and osteophyte severity, and with OA progression based on osteophyte score. Urinary α-CTX localized primarily to high bone turnover areas in subchondral bone. CTX-II localized to the bone-cartilage interface, the tidemark, and damaged articular cartilage. CONCLUSION: Baseline urinary α-CTX, which was localized to high turnover areas of subchondral bone, was associated with dynamic bone turnover of knees, as signified by scintigraphy, and progression of both osteophytes and JSN. Urinary CTX-II correlated with JSN and osteophyte severity and progression of osteophytes. To our knowledge, this represents the first report of serologic markers reflecting subchondral bone turnover. These collagen markers may be useful for noninvasive detection and quantification of active subchondral bone turnover and joint remodeling in knee OA.
OBJECTIVE: To evaluate joint tissue remodeling using the urinary collagen biomarkers urinary α-C-telopeptide of type I collagen (α-CTX) and urinary C-telopeptide of type II collagen (CTX-II) and to determine the association of these biomarkers with osteoarthritis (OA) severity, progression, and localized knee bone turnover. METHODS:Participants (n = 149) with symptomatic and radiographic knee OA underwent fixed-flexion knee radiography at baseline and 3 years, and late-phase bone scintigraphy of both knees at baseline, which were scored semiquantitatively for osteophyte and joint space narrowing (JSN) severity and uptake intensity, with scores summed across knees. Urinary concentrations of α-CTX and CTX-II were determined by enzyme-linked immunosorbent assay. Immunohistochemical analysis of human OA knees was performed to localize the joint tissue origin of the biomarker epitopes. RESULTS: Urinary α-CTX concentrations correlated strongly with the intensity of bone scintigraphic uptake and with JSN progression (risk ratio 13.2) and osteophyte progression (risk ratio 3). Urinary CTX-II concentrations were strongly associated with intensity of bone scintigraphic uptake, with JSN and osteophyte severity, and with OA progression based on osteophyte score. Urinary α-CTX localized primarily to high bone turnover areas in subchondral bone. CTX-II localized to the bone-cartilage interface, the tidemark, and damaged articular cartilage. CONCLUSION: Baseline urinary α-CTX, which was localized to high turnover areas of subchondral bone, was associated with dynamic bone turnover of knees, as signified by scintigraphy, and progression of both osteophytes and JSN. Urinary CTX-II correlated with JSN and osteophyte severity and progression of osteophytes. To our knowledge, this represents the first report of serologic markers reflecting subchondral bone turnover. These collagen markers may be useful for noninvasive detection and quantification of active subchondral bone turnover and joint remodeling in knee OA.
Authors: Anke J Roelofs; Charlotte A Stewart; Shuting Sun; Katarzyna M Błażewska; Boris A Kashemirov; Charles E McKenna; R Graham G Russell; Michael J Rogers; Mark W Lundy; Frank H Ebetino; Fraser P Coxon Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman Journal: Osteoarthritis Cartilage Date: 2011-03-23 Impact factor: 6.576
Authors: Virginia Byers Kraus; Sheng Feng; ShengChu Wang; Scott White; Maureen Ainslie; Marie-Pierre Hellio Le Graverand; Alan Brett; Felix Eckstein; David J Hunter; Nancy E Lane; Mihra S Taljanovic; Thomas Schnitzer; H Cecil Charles Journal: Arthritis Rheum Date: 2013-07
Authors: Leticia A Deveza; Virginia B Kraus; Jamie E Collins; Ali Guermazi; Frank W Roemer; Michael Bowes; Michael C Nevitt; Christoph Ladel; David J Hunter Journal: Arthritis Care Res (Hoboken) Date: 2017-07-10 Impact factor: 4.794
Authors: Virginia Byers Kraus; Jamie E Collins; David Hargrove; Elena Losina; Michael Nevitt; Jeffrey N Katz; Susanne X Wang; Linda J Sandell; Steven C Hoffmann; David J Hunter Journal: Ann Rheum Dis Date: 2016-06-13 Impact factor: 19.103
Authors: Olivier Bruyère; Cyrus Cooper; Nigel Arden; Jaime Branco; Maria Luisa Brandi; Gabriel Herrero-Beaumont; Francis Berenbaum; Elaine Dennison; Jean-Pierre Devogelaer; Marc Hochberg; John Kanis; Andrea Laslop; Tim McAlindon; Susanne Reiter; Pascal Richette; René Rizzoli; Jean-Yves Reginster Journal: Drugs Aging Date: 2015-03 Impact factor: 3.923